Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Target of Myb1-like protein 1 (TOM1L1)
- Target
- TOM1L1
- Molecular classification
- Adapter protein (scaffold protein), Membrane trafficking regulator (post-Golgi trafficking), VHS domain-containing protein, GAT domain-containing protein, Clathrin-binding protein
01
Overview
Target of Myb1-like protein 1 (TOM1L1) is an adapter protein with VHS and GAT domains, which functions in membrane trafficking and signal transduction. TOM1L1 interacts with SH2 and SH3 domain-containing proteins and is implicated in clathrin-mediated trafficking as well as tyrosine kinase signaling regulation. It negatively regulates mitotic activity and protein phosphorylation, localizing to cytosol and endosome. TOM1L1 is frequently co-amplified with ERBB2 (Her2) in breast cancer, enhancing tumor cell invasiveness through a mechanism independent of its historical SRC association, instead facilitating trafficking of the metalloprotease MT1-MMP to invadopodia for extracellular matrix degradation. TOM1L1 amplification is linked to poor prognosis in HER2-positive breast cancer patients and is emerging as a molecular marker for aggressive cancers and possible therapeutic interventions.
- Other names
- TOM1-like protein 1TOM1L1SRCASMSrc-activating and signaling molecule proteinTarget of Myb-like protein 1
02
Mechanism of action
Inhibition of ERBB2-driven cell invasion by blocking ERBB2 signaling or reducing the delivery of MT1-MMP to invadopodia (as demonstrated by Lapatinib)
03
Biological functions
Signal transductionNegative regulation of mitotic nuclear divisionPositive regulation of protein phosphorylationProtein trafficking, especially post-Golgi and endocytic compartment trafficRegulation of tyrosine kinase signalingRegulation of EGFR endocytosis and lysosomal degradationAssociation with invadopodia formation and cell invasion
04
Disease associations
Cancer (breast cancer, especially ERBB2/Her2-positive subtypes; bone metastasis)Potential role in broader oncogenic signaling pathways-driven malignancy
05
Safety considerations
Potential challenge is off-target inhibition impacting normal endocytic and trafficking processes, signaling, and mitotic regulation, but no direct toxicities are documented for TOM1L1 targeting as of now
06
Interacting drugs
Lapatinib
07
Biomarkers
TOM1L1 amplification and/or protein expression (as detected by IHC or other assays), particularly in HER2(ERBB2) positive breast cancers, associated with poor prognosis and increased invasiveness
Beyond the preview
Go deeper on Target of Myb1-like protein 1 (TOM1L1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Target of Myb1-like protein 1 (TOM1L1).